NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Market Closed 08-14 16:00:00 EDT

14.77

+0.26

+1.79%

盘后14.77

+0.000.00%

19:34 EDT

High14.80	Low14.29	Vol154.96K
Open14.46	D1 Closing14.51	Amplitude3.51%
Mkt Cap503.56M	Tradable Cap343.86M	Total Shares34.09M
T/O2.27M	T/O Rate0.67%	Tradable Shares23.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":14.77,"timestamp":1786737600000,"preClose":14.51,"halted":0,"volume":154960,"hourTrading":{"tag":"盘后","latestPrice":14.77,"preClose":14.77,"latestTime":"19:34 EDT","volume":121,"amount":1785.8,"timestamp":1786750447795,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017918676774638168,"floatShares":23281000,"shares":34093745,"eps":-0.569031,"marketStatus":"Market Closed","change":0.26,"latestTime":"08-14 16:00:00 EDT","open":14.46,"high":14.8,"low":14.29,"amount":2268452.62176,"amplitude":0.035148,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.569031,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":14.51,"postHourTrading":{"tag":"盘后","latestPrice":14.77,"preClose":14.77,"latestTime":"19:34 EDT","volume":121,"amount":1785.8,"timestamp":1786750447795,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.787930867873719,"impliedVol":0.6851,"impliedVolPercentile":0.5578},"requestUrl":"/m/hq/s/NPCE/","defaultTab":"news","newsList":[{"id":"2658418109","title":"NeuroPace Forecasts 2026 Revenue USD 99.5 Million-101.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658418109","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658418109?lang=en_us&edition=fundamental","pubTime":"2026-08-12 07:02","pubTimestamp":1786489358,"startTime":"0","endTime":"0","summary":"NeuroPace forecasts 2026 revenue USD 99.5 million-101.5 millionNeuropace forecast 2026 revenue of $99.5 million to $101.5 million, targeting 21%-23% RNS revenue growth.Non-GAAP gross margin outlook of 82%-83%.Non-GAAP operating expense guidance of $90 million to $92 million.Adjusted EBITDA expected at a loss of $7.5 million to $8.5 million.Forecast follows Q2 2026 RNS revenue of $22.5 million, up 21% year over year, with adjusted gross margin of 83.4%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLb5k8nP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945783","title":"NeuroPace, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945783","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945783?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:02","pubTimestamp":1786482146,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. reports results for the quarter ended June 30 - Earnings SummaryNeuroPace, Inc.NPCE.OQreported a quarterly adjusted loss of 18 cents per share for the quarter ended June 30, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448270:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948736","title":"NeuroPace Rugi Bersih GAAP Q2 FY26 Menyempit 38,1% Jadi USD 6,2 Juta; Revenue Naik 17% Jadi USD 22,8 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948736","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948736?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:09","pubTimestamp":1786478972,"startTime":"0","endTime":"0","summary":"NeuroPace rugi bersih GAAP Q2 FY26 menyempit 38,1% jadi USD 6,2 juta; revenue naik 17% jadi USD 22,8 jutaNeuroPace membukukan revenue kuartal II 2026 sebesar USD 22,8 juta, naik 17% dibanding kuartal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4g5GwL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NPCE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658481479","title":"NeuroPace, Inc. Q2 EPS Usd -0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2658481479","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658481479?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:06","pubTimestamp":1786478761,"startTime":"0","endTime":"0","summary":"BRIEF-NeuroPace, Inc. Q2 EPS USD -0.18Aug 11  - NeuroPace, Inc. Q2 revenue USD 22.826 million vs. IBES estimate USD 22.7 million.Q2 net income USD -6.2 millionQ2 operating expenses USD 24.049 millionQ2 gross profit USD 18.906 millionoutlook FY revenue USD 99.5-101.5 million vs. IBES estimate USD 99.9 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXKWQMXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658489869","title":"Neuropace, Inc. Q2 EPS Usd -0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2658489869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658489869?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXKWQMXR:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658482889","title":"Press Release: NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658482889","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658482889?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478700,"startTime":"0","endTime":"0","summary":"--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth----Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS revenue from existing indications----Preparation remains on track for SIR meeting with FDA regarding the IGE PMA supplement, supported by 24-month NAUTILUS data showing a 100% median reduction in GTC seizures among evaluable patients --MOUNTAIN VIEW, Calif.----August 11, 2026--NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.Second Quarter 2026 Financial Highlights--  Total revenue of $22.8 million in the second quarter of 2026. --  RNS System revenue of $22.5 million in the quarter, representing 21.3%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657462984","title":"NeuroPace, Inc. Expected to Post a Loss of 21 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657462984","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657462984?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:45","pubTimestamp":1786135505,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. <NPCE.OQ> expected to post a loss of21cents a share - Earnings PreviewNeuroPace, Inc.NPCE.OQNPCE.Ois expected to  show a fall in quarterly revenue when it reports  results on August 10","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655897738","title":"Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655897738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655897738?lang=en_us&edition=fundamental","pubTime":"2026-07-30 01:10","pubTimestamp":1785345028,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB), NeuroPace (NPCE) and Gilead Science...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biogen-biib-neuropace-npce-and-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biogen-biib-neuropace-npce-and-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","BK4588","LU0965509010.AUD","LU1839511570.USD","BK4139","IE00BKVL7J92.USD","LU0234570918.USD","LU2087621335.USD","LU1430594728.SGD","IE00B19Z9Z06.USD","BMED","LU1066053197.SGD","LABU","BIIB","LU1037948897.HKD","LU1778281490.HKD","LU2089984988.USD","LU0109394709.USD","LU1571399168.USD","LU0861579265.USD","LU0058720904.USD","MEDI","NPCE","XLV","LU0965508806.USD","LU0889565916.HKD","BK4533","BK4583","GILD","TMED","LU1057294990.SGD","SG9999015978.USD","LU0114720955.EUR","BK4568","LU0882574055.USD","HCSG","LU1023059063.AUD","LU0289739699.SGD","LU2112291526.USD","BIB","IBBQ","LU0122379950.USD","XBI","IE00B3T34201.USD","LU1934455277.USD","TBXU","IE00B7SZLL34.SGD","BBH","PBE","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981108","title":"NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981108","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981108?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:40","pubTimestamp":1785328817,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE) on Tuesday provided an update on the U.S. Food and Drug Administration review of the company’s Premarket Approval Panel Track Supp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-fda-seeks-additional-clinical-evidence-from-nautilus-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-fda-seeks-additional-clinical-evidence-from-nautilus-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LABU","NPCE","BK4539","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861478","title":"NeuroPace Price Target Maintained with a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861478?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:56","pubTimestamp":1785322560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655833603","title":"NeuroPace faces FDA setback on epilepsy label expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2655833603","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655833603?lang=en_us&edition=fundamental","pubTime":"2026-07-29 05:01","pubTimestamp":1785272494,"startTime":"0","endTime":"0","summary":"NeuroPace ( ($NPCE) ) has provided an announcement. On July 28, 2026, NeuroPace announced that the U.S. Food and Drug Administration had determined...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-faces-fda-setback-on-epilepsy-label-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-faces-fda-setback-on-epilepsy-label-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385548","title":"NeuroPace Says FDA Deems Epilepsy Label Expansion Filing not Approvable in Current Form","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385548","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655385548?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:33","pubTimestamp":1785270784,"startTime":"0","endTime":"0","summary":"NeuroPace says FDA deems epilepsy label expansion filing not approvable in current formFDA told NeuroPace its PMA panel-track supplement to expand RNS into drug-resistant idiopathic generalized epilep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL4Mr8G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655887953","title":"Neuropace - Receives FDA Notice Pma Supplement for Ige not Approvable in Current Form","url":"https://stock-news.laohu8.com/highlight/detail?id=2655887953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655887953?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:01","pubTimestamp":1785268860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA7KSTK5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655887611","title":"Neuropace - to Submit Submission Issue Request and Amend Pma Supplement","url":"https://stock-news.laohu8.com/highlight/detail?id=2655887611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655887611?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:01","pubTimestamp":1785268860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA7KSTK5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655876128","title":"Neuropace Receives FDA Guidance on Pma Supplement for Indication Expansion into Idiopathic Generalized Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655876128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655876128?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:01","pubTimestamp":1785268860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA7KSTK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655588762","title":"Neuropace - FDA Requests Additional Clinical Evidence from Nautilus Trial for Pma Supplement","url":"https://stock-news.laohu8.com/highlight/detail?id=2655588762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655588762?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:01","pubTimestamp":1785268860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA7KSTK5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741579","title":"Neuropace Inc : Mizuho Initiates Coverage with Outperform Rating; Target Price $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741579?lang=en_us&edition=fundamental","pubTime":"2026-07-23 18:54","pubTimestamp":1784804051,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43P0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NPCE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642373244","title":"NeuroPace Shareholders Approve Directors and Auditor at Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642373244","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642373244?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:26","pubTimestamp":1780957619,"startTime":"0","endTime":"0","summary":"NeuroPace ( ($NPCE) ) has shared an update. On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders virtually, where sharehol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642434930","title":"NeuroPace shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642434930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642434930?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:55","pubTimestamp":1780952106,"startTime":"0","endTime":"0","summary":"Neuropace held its 2026 annual shareholder meeting on June 5, 2026.Shareholders selected Lisa Andrade, Scott Huennekens as Class II directors with terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL72FNNn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639222056","title":"NeuroPace attends ASSFN meeting, spotlights expanding role of responsive neuromodulation in epilepsy care","url":"https://stock-news.laohu8.com/highlight/detail?id=2639222056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639222056?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:06","pubTimestamp":1780056409,"startTime":"0","endTime":"0","summary":"NeuroPace will attend the ASSFN Meeting in Cleveland, Ohio, running May 29–June 2, 2026.Company plans to highlight long-term RNS System outcomes, NAUTILUS results in idiopathic generalized epilepsy, supported by data-driven clinical tools.A breakfast symposium on thalamic neuromodulation is scheduled for June 1, 2026, 7:00 a.m. ET.NeuroPace will support an epilepsy surgery education course on May 30, 2026, 8:30 a.m.–12:00 p.m. ET.Booth demonstrations and physician feedback sessions are planned throughout the meeting, including a preview of the FDA-cleared ECoG Assistant tool.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on May 29, 2026, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLKz1nF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuropace.com;investors.neuropace.com","stockEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":-0.0888},{"period":"3month","weight":-0.0384},{"period":"6month","weight":-0.0186},{"period":"1year","weight":0.6357},{"period":"ytd","weight":-0.0434}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.513635},{"month":2,"riseRate":0.4,"avgChangeRate":0.014939},{"month":3,"riseRate":0.2,"avgChangeRate":-0.075134},{"month":4,"riseRate":0.4,"avgChangeRate":0.054856},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.123698},{"month":6,"riseRate":0.5,"avgChangeRate":-0.043589},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066491},{"month":8,"riseRate":0.666667,"avgChangeRate":0.205121},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065676},{"month":10,"riseRate":0,"avgChangeRate":-0.132059},{"month":11,"riseRate":0.6,"avgChangeRate":0.163487},{"month":12,"riseRate":0.6,"avgChangeRate":0.015944}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction